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 Summary
INTRODUCTION
 Leprosy ancient disease also called Hansen’s disease, is a chronic, progressive infectious 
disease caused by the bacterium Mycobacterium leprae. An obligate intracellular parasite, and a 
close relative of the Mycobacterium tuberculosis. It primarily affects the nerves of the extremities 
(peripheral nerves), the lining (mucous membranes) of the nose, eyes, and the upper respiratory 
tract. It produces skin sores, nerve damage, and muscle weakness leading to deformity and erosion.
AIM
 This review article was to theorize and hypothesize the recurrence of unique human, 
M. leprae or environmental characteristics that favour the endemicity, prolonged survival and 
Leprosy transmission in the affected epidemiologic regions, including parts of Kenya. Highlight 
the age old traditional line of perception about this disease
 
OBJECTIVE 
 Even though global efforts to control Leprosy by intensive multi-drug chemotherapy 
(MDT) since 1964 have led to a significant decrease in the number of reported new cases. The 
disease continues to be endemic in many epidemiologic regions. Some regions experiencing 
increasing incidence. 
 The disease has afflicted humankind throughout history leaving evidence in both early 
texts and archaeological record. Leprosy’s origins have reportedly existed as late as 3,500 BC. 
However, some of the earliest written records that accurately reflect leprosy appears to be from the 
600 BC Sushruta Samhita text from India. The interplay of emotional and social factors modify 
or transform the life programme of persons afflicted with leprosy. Just like the current pandemic 
cancers, Leprosy is still a crucial global health concern. The MDT for leprosy was designed to 
prevent emergence and transmission of drug-resistant M. leprae strains. However, in the African 
epidemiologic regions, Peer reviewed articles on the Internet, Journals and Relevant topics in 
textbooks were reviewed.
METHODOLOGY
 A literature review was done to up-date the socio-cultural perception of leprosy in Indian 
religions and ancient texts' references were obtained through examining relevant bibliographies 
and the views/suggestions of eminent scholars engaged in this field
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 A Sociological study was carried out in respondents of a Lepers Colony (Gandhi Kusth 
Ashram), Jodhpur, India. An attempt was made to study the knowledge about causation of Leprosy, 
age at onset, and treatment. The reason for leaving their original place of origin (South India) was 
asked. A majority (95.2%) of patients were Hindus, had onset of leprosy in the age group of below 
20 to 30 years (80.94%) they had a literacy rate of 6.3% only. 
 Leprosy is most challenging to behavioral scientists interested in the description and 
theory of medical sociology as  a psychosocial phenomenon. However, the country is currently 
battling with resurgence of the disease, which is characterized with high numbers of relapses. 
CONCLUSION
 The observed continued endemicity and increasing incidence of leprosy in some 
epidemiologic regions raised the assumption of the existence of unique human, M. laprae or 
environmental factors that favour prolonged survival and transmission of M. leprae. Unique 
strains of M. leprae with selective advantage to circumvent BCG induced immunity, or resistant 
to anti-leprotic drugs may also have emerged. Further interrogation of this assumption could 
generate valuable information for improved control of leprosy.
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in humans and a peripheral neuropathy initiated by the 
infection and the accompanying immunological events. 
 Leprosy is curable but not preventable. It 
remains a major global health concern in the low income 
countries, publicity to the contrary notwithstanding [2]. 
 Therefore calls for constant and continuous 
focus and surveillance of the disease for sustainable and 
improved management, aimed at its total elimination.
 This review article consolidates the historical, 
social, spiritual, biological and epidemiological 
perspectives of leprosy globally, with some emphasis 
laid on Kenya. It digs into the drivers of the diseases 
and mitigation mechanisms currently in place and the 
challenges encountered. It examines recent global trends 
of the disease, and critical issues and challenges related 
to transmission of the disease resulting from hidden 
cases and delayed detection and initiation of treatment. 
 Drivers of transmission of the disease are also 
addressed. The impending threat of complacency and 
potential loss of the hard-earned success and gains thus 
far against the disease are discussed, together with the 
impact of the stigma associated with the disease on both 
the individual and the community. 
Introduction
 Leprosy,  also called Hansen’s disease, is 
a chronic, progressive infectious disease caused 
by the bacterium Mycobacterium leprae, an 
obligate intracellular parasite, a close relative of the 
Mycobacterium tuberculosis. It primarily affects the 
nerves of the extremities (peripheral nerves), the lining 
(mucous membranes) of the nose, eyes, and the upper 
respiratory tract. Leprosy produces skin sores, nerve 
damage, and muscle weakness. 
 Destruction of nerves by M. leprae leads to 
a loss of sensation, which, together with progressive 
tissue degeneration, leads to the extremities’ becoming 
deformed and eroded. 
 If not treated early enough, leprosy causes 
severe disfigurement and significant disability. The 
disease is characterized by the formation of nodules or 
macules that enlarge and spread accompanied by loss 
of sensation with eventual paralysis, wasting of muscle, 
and production of deformities [1]. 
 Leprosy is best understood as two conjoined 
diseases: a chronic mycobacterial infection that elicits 
an extraordinary range of cellular immune responses 
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 Finally, the review advances a number of 
recommendations, some quite innovative, and the way 
forward so as to safeguard gains made thus far against 
the disease and give further impetus on the war against 
this ancient disease.
Origin and History of Leprosy 
 Leprosy has afflicted humankind throughout 
history leaving evidence in both early texts and the 
archaeological records. 
 For instance in Britain, leprosy was 
widespread throughout the Middle Ages until it's 
gradual and unexplained decline between the 14th 
and 16th centuries. The nature of this ancient endemic 
disease with its relationship to modern health strains 
is not well understood [3]. 
 Throughout history, individuals with leprosy 
have been known as ‘lepers’. In the 21st century, the 
term “leprosy” is falling into disuse as a result of the 
diminishing number of leprosy patients. Because of the 
stigma to patients, some authors prefer not to use the 
word "leprosy," and prefer to use "Hansen's disease." 
 However, the term "leprosy" is still used by the 
WHO [4 ]. The history of leprosy was traced by geneticists 
in 2005 through its origins and global distribution using 
comparative genomics. They suggested that leprosy 
originated in East Africa or the Near East and traveled 
with humans along their migration routes, including 
those of trade in goods and slaves. 
 The four (1, 2, 3, 4) strains of M. leprae are 
based in specific geographical regions:
a. Strain 1 occurs predominantly in East Africa,  
 Asia, and the Pacific region.
b. Strain 2 in Ethiopia, Malawai, Nepal/North  
 India, and New Caledonia.
c. Strain 3 in Europe, North Africa, and the  
 Americas.
d. Strain 4 in West Africa and the Caribbean.  
 They created a map of the dissemination of  
 leprosy in the world. 
 This confirmed the spread of the disease along 
the migration, colonization, and slave trade routes taken 
from East Africa to India, West Africa to the New 
World, and from Africa into Europe and vice versa [5]. 
 The causative agent of leprosy, M. leprae, was 
discovered by the Norwegian G. H. Armauer Hansen 
(1841-1912) in 1873. This was the first bacterium to be 
identified as causing disease in humans [6].
 At some point, the origin of syphilis (a sexually 
transmitted bacterial disease) was said to have been 
some form of leprosy. In this Pre-Columbian theory 
of the origin of syphilis, it is argued that syphilis was 
present in Europe for several hundred years before the 
sailor Christopher Columbus returned from the New 
World (The Americas, Africa and Asia). 
 This arises from the European Medical 
Literature of the 1200s – 1300s that describe certain 
highly contagious forms of ‘leprosy’ that could be 
sexually and congenitally (in – utero) transmitted. This 
form of ‘leprosy’ responded well to mercury treatment, 
one of the mainstays of treating the ‘Great Pox’, hence 
may have been syphilis. It has many synonyms, the 
‘Great Pox’ being one of them [7].
 The history of leprosy cannot be complete 
without touching its religious perspective. Although 
leprosy’s origins have been reportedly existed as late as 
3,500 Before Christ (3500 BC) which also means 3,500 
Before Common Era BCE (3,500 BCE) in papyrus 
documenting the illness of the Egyptian king Hispati. 
The earliest written records which accurately reflect 
leprosy as to be from the 600 BCE Sushruta Samhita 
text from India. 
 Indeed, recollections of leprosy throughout 
mankind’s history have been fraught with confusion, 
with much controversy in determining who had indeed 
been infected with leprosy, instead of other diseases 
such as smallpox or plague [8]. 
 Leprosy has terrified humanity since ancient 
times and was reported as early as 600 BC in India, 
China, and Egypt [9]. 
 Leprosy, currently known as Hansen’s disease, 
is still a major health problem in many parts of Africa, 
Asia, and Latin America [8]. 
 For many centuries, leprosy was considered a 
curse from God.  Often associated with sin. It did not 
kill, but neither did it seem to end. Instead, it lingered for 
years, causing the tissues to degenerate and deforming 
the body [10-12].
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 The term “leprosy” (including leper, lepers, 
leprosy, leprous) occurs 68 times in the holy Bible; 
a total of 55 times in the Old Testament (Hebrew = 
tsara’ath) and 13 times in the New Testament (Greek 
= lepros, lepra). In the Old Testament, the instances of 
leprosy most likely meant a variety of infectious skin 
diseases, and even mold and mildew on clothing and 
walls. 
 The precise meaning of the leprosy in both the 
Old and New Testaments is still in dispute, but it probably 
includes the modern Hansen’s disease (especially in the 
New Testament) and infectious skin diseases [8]
 References to leprosy have a different emphasis 
in the New Testament of the Holy Bible. They stress 
God’s desire to heal. Jesus freely touched people with 
leprosy. While people with leprosy traditionally suffered 
banishment from family and neighbours, Jesus broke 
from the tradition. 
 He treated lepers with compassion, touching and 
healing them. Although we can’t know all the reasons 
that God allows disease into our lives, biblical leprosy is 
a powerful symbol reminding us of sin’s spread and its 
horrible consequences. 
 Like leprosy, sin starts out small but can then 
spread, leading to other sins and causing great damage 
to our relationship with God and others [13-16]. 
 Disease is a constant reminder of just how much 
things have changed since God pronounced a curse on 
the earth. At first, everything was “very good,” but 
Adam’s sin brought death and decay into the world. One 
of the most well-known examples of debilitating disease 
in this sin-cursed creation is M. leprae, the infectious 
bacterial agent of leprosy. 
 Leprosy is discussed quite often in the Bible. 
While its definition in modern times is different from 
biblical times, there is no doubt that the definitions 
overlap, and the modern form of the disease still 
illustrates important spiritual lessons today [16].
 According to Brand, studying leprosy helps 
us appreciate why pain is a valuable “gift,” a survival 
mechanism to warn us of danger in this cursed world. 
Without pain and suffering, we might be like lepers, 
unable to recognize that something is terribly wrong 
and that we need the healing touch of God.
 “I cannot think of a greater gift that I could give my 
leprosy patients than pain [17].”
In Leviticus 13:45-47:
“The person who has the leprous disease
 shall wear torn clothes and 
Let the hair of his head be disheveled; 
And he shall cover his upper lip 
And cry out, ‘Unclean, unclean.’…
 He shall live alone…” [9].
 
 Actually, some leprosy patients have had their 
fingers eaten by rats in their sleep because they were 
totally unaware of it happening; because lack of pain 
receptors could not warn them of the danger. 
 The best example in the holy Bible of a person 
with Hansen’s disease is the man with the withered hand 
[13-15]. He likely suffered from Tuberculoid leprosy [8].
Sociology Of Leprosy
 Leprosy is one of the oldest ailments known 
to mankind. Many of the ancient texts and scriptures 
reveal that leprosy was not categorized as a specified 
disease but was grouped along with other skin diseases. 
 However, in certain texts categorical mention 
of this disease does exist. The prime objective of this 
article is to highlight the age old traditional line of 
perception about this disease. A literature review was 
done to up-date the socio-cultural perception of leprosy 
in Indian religions and ancient texts.
Methodology
 References were obtained through examining 
relevant bibliographies and the views/suggestions 
of eminent scholars engaged in this field were also 
included. An analysis of the secondary sources of data, 
particularly the ancient texts reveals that in good old 
days, leprosy had been considered to be an infliction 
of wrong-doings and sins. This viewpoint has been 
significantly reflected in these texts [18].
 A Sociological study was carried out in 
respondents of a Lepers Colony (Gandhi Kusth 
Ashram), Jodhpur, India. An attempt was made to study 
the knowledge about causation of Leprosy, age at onset, 
and treatment. 
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 The reason for leaving their original place of 
origin (South India) was queried. A majority (95.2%) of 
patients were Hindus, had onset of leprosy in the age 
group of below 20 years to 30 years (80.94%) had a 
literacy rate of 6.3% only. 
 A history of contact with a case of leprosy could 
be traced in 38% but within the family only in 11.9%. 
The infection as a cause of leprosy was recognized 
only by 3.57% patients but a majority had no idea about 
aetiology (70.24%) or thought it to be due to punishment 
for past sins (3.57%) or due to supernatural causation 
(1.19%). Most of them (70.2%) left home for fear of 
losing family prestige and to hide the disease (25.00%) 
or hatred of other family members (4.76%) [19].
 The interplay of emotional and social factors 
modify or transform the life programme of persons 
afflicted with a chronic illness such as leprosy. While 
leprosy has many of the characteristic effects on the 
patient found in other chronic conditions, from the 
standpoint of therapy, surgical intervention, or even 
physical incapacity, leprosy presents certain advantages 
to a social psychological investigation of chronic 
illness. This is due to the fact that social and emotional 
experiences and phenomena play an exceedingly 
important role in patient outcomes in leprosy, factors 
that at times surpass the physical facts of deformity and 
dysfunction in modifying the person's career. 
 Leprosy is most challenging to behavioral 
scientists interested in the description and theory of 
medical sociology as  a psychosocial phenomenon [20].
 It is a kind of social stigma, a strong feeling 
that a leprosy patient is shameful and is not accepted 
normally in a society. It is also called leprosy-related 
stigma, leprostigma, and stigma of leprosy [21]. 
 From ancient times the disease was feared 
because of the disfigurement it caused and lack of 
understanding about how it was transmitted. It was long 
believed to be inherited and was associated with ideas 
of "unclean blood". 
 The stigma was renewed in the late nineteenth 
century as Europeans encountered cultures where 
leprosy was or became more widespread than in their 
own, or where it was associated with poverty and 
developing economies. An example was in Hawai̒ i, 
where European Americans, particularly sugar planters, 
supported legislation to quarantine persons with leprosy 
in the belief that this would prevent its transmission.
 United States sociologist defined "stigma" as an 
attribute that is deeply discrediting.
 
1. A stigmatized individual is one who is not  
 accepted and not accorded the respect and  
 regard of his peers, 
2. Who is disqualified from full social acceptance. 
 It is associated with physical deformities, and 
blemishes of character such as are associated with 
alcoholism and drug addition [22]. 
 It is also associated with race, nation, social 
class, sexuality and religion that are thought of as 
second-class by other groups. Social stigma means the 
disapproval of (or discontent with) a person based on 
socially characteristic grounds that are perceived, and 
serve to distinguish them, from other members of a 
society [21].
 In a paper entitled "Leprosy stigma", citing 
the definition of stigma by describing three types of 
stigmatized individuals associated with the disease 
leprosy; 
 
1. Those with physical deformities, such as facial  
 plaques, facial palsy, claw hand deformity or  
 foot-drop
 
2. Those presumed to have a blemished character,  
 as in persons confined to a leprosarium; and  
 tribal stigma, or people belonging to a poor  
 social class [22,23]. 
 Leprosy stigma has a rich history. It has been 
associated with the disease for time memorial. It has 
been universal, and present in all areas of the world. It 
was noted that 
“The impact of the meaning of the disease
 May be a greater source of suffering 
Than symptoms of the disease” [24]. 
  In Western Europe, Leprosy stigma 
reached its peak in the Middle Ages, at a time when the 
disease was viewed as rendering the person "unclean". 
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Many "lazar houses" were built. Patients had to carry 
bells to signal their presence but also to attract charitable 
gifts [21].
 The finding in 1873 by Hansen that, leprosy was 
infectious and transmitted by a bacterium worsened the 
leprosy stigma. It was for long associated with sexually 
transmitted disease and during the nineteenth century 
was thought to be a stage of syphilis.  
 As already stated elsewhere, this arises from the 
European medical literature of the 1200s – 1300s that 
describe certain highly contagious forms of ‘leprosy’ 
that could be sexually and congenitally (in – utero) 
transmitted [7, 25, 26]. 
 The stigma of the disease was renewed among 
Europeans in the imperial era when they found it was 
"hyper epidemic in regions that were being colonized." 
It became associated with poor, developing countries, 
whose residents were believed by Europeans to be 
inferior in most ways [21]. 
 Since the late twentieth century, with efforts by 
the WHO to control the disease through distribution of 
free medication, many international organizations have 
been working to end the stigma attached to leprosy. 
They work to educate people and raise awareness of the 
facts about leprosy, in particular that it is only mildly 
contagious; some 95% of people are immune to the 
bacterium that causes it [21]. 
Epidemiology of leprosy
  
 Leprosy is listed as a neglected tropical disease. 
It is an old disease that continues to be crucial public 
health problem in several developing countries. 
 In over 100 countries the disease is endemic 
and in twelve countries (Bangladesh, Brazil, DR Congo, 
Ethiopia, India, Indonesia, Madagascar, Mozambique, 
Myanmar, Nepal, Nigeria and Tanzania) the prevalence 
is still above the benchmark set by the World Health 
Organization of 1 new case per 10,000 inhabitants per 
year [27]. 
 There has been a steady increase of leprosy 
cases since early 1990s. In the year 1991 a total of 
584,000 new cases were reported worldwide. The global 
detection reached a peak of 820,000 new cases in 1998 
and then leveled at around 750,000 cases during the 
following years [28]. 
 However, the prevalence of the disease is variate 
with the overwhelming majority of cases being in the 
developing countries. In 2009, India, Brazil, Indonesia, 
Bangladesh, and Nigeria were among the 16 countries 
that reported more than 1000 new cases annually the 
greatest numbers of the cases [29].
 
 With increasing international travel, however, 
patients with leprosy may present anywhere. 
 Apparently, between 1985 and 2011, the number 
of registered leprosy cases fell from 5.4 million to 
219,075; the prevalence rate per 10,000 fell from 21.1 to 
0.37; these figures exclude Europe [30].
 As at 2002, Brazil, India, Nepal, Myanmar, 
Madagascar and Mozambique contributed almost 90% 
to the leprosy cases registered worldwide [31, 32], and 
80%. of all leprosy cases of the Americas occur in Brazil 
[33]. 
 However, the disease was unevenly distributed 
within Brazil: the North-east Region, the poorest region 
in the federation, reported 33.5% of newly diagnosed 
cases (3.2 cases per 10 000 inhabitants) whereas the 
industrialized South region, one of the richest, reported 
only 4.1% (0.7 cases per 10 000 inhabitants) in 2002 
[34]. 
 The new case detection rate in the North-east 
was twice that of the average of the country as a whole 
and increased over the last decade [35].
 The WHO [36] has zoned the world into 6 
epidemiological regions. These are: 
 1. Africa region (AFR)
 2. Region of the Americas (AMR)
 3. Eastern Mediterranean Region (EMR) 
 4. European Region (EUR) 
 5. South East Asia Region (SEAR) 
 6. Western Pacific Region (WPR) 
 The disease burden varies from region to region 
(Table 1) next page..........
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Table 1:  Registered Prevalence* (Shown In Parenthesis) Of Leprosy and Number Of New Cases Reported By
              WHO Regions For  2010-2016 Period
Year 2010 2011 2012 2013 2014 2015 2016
AFR 25 345 (3.53) 12 673 (3.14) 20 599 (3.05) 20 911 (3.50) 18 597(2.44) 20004(2.6) 19384(2.0)
SEAR 156 254(8.77) 160 132 (8.75) 166 445(8.98) 155 385(8.38) 154 834(8.12) 156 118(8.1) 161263(8.2)
AMR 37 740 (4.25) 36 832 (4.18) 36 178 (4.14) 33 084 (3.78) 33 789(3.75) 28 806(3.2) 27 356(2.7)
EMR 4 080 (0.67) 4 346 (0.71) 4 235 (0.72) 1 680 (0.35) 2 342(0.38) 2 167(0.3) 2 834(0.4)
WPR 5 055 (0.28) 5 092 (0.30) 5 400 (0.30) 4 596 (0.25) 4 337(0.24) 3 645(0.2) 3 914(0.2)
EUR++ - - - - - 18(0.004) 32
Total 228 474 (3.93) 181 941 (0.34) 232 857 (4.00) 215,656 (3.81) 213 899(3.78) 210 758(3.2) 214783 (2.9)
Source: WHO [36].http://www.who.int/wer/en/
*Prevalence per 100 000 population
++Reports from EUR were received in the past 2 years only
 Worldwide there was a marginal increase in the 
number of new cases reported during the year (2016) in 
terms of absolute number.  
 A total of 143 countries filed leprosy reports 
from the 6 WHO regions in the year 2016 as follows: 
1. 31 of 48 countries in the AFR 
2. 25 of 49 countries in the AMR 
3. 16  of 22 countries in the EMR 
4. 29 of 53  countries in the EUR
5. 9   of 11  countries in the SEAR
6. 33 of 37  countries and territories in the  
   WPR. 
 The e-filing of reports helped in collecting 
information on different aspects of the leprosy 
programme, in line with the monitoring and evaluation 
guide of the Global Leprosy Strategy. 
 In total 214,783 new cases were reported from 
the 143 countries during that year 2016, corresponding 
to the global new-case detection rate of 2.9 per 100,000 
population [37].
 In the year 2015, the global prevalence of 
leprosy was 176,176 cases (0.2 cases per 10,000 people) 
with 211,973 new cases (2.9 new cases per 100,000 
people) according to reports from 138 countries in all 
World Health Organization regions. There were 215,656 
and 213,899 new cases of leprosy in 2013 and 2014, 
respectively. 
 Global statistics imply that 94% of new leprosy 
cases were from 14 countries with more than 1,000 new 
cases in each, and only 6% of new cases were in the rest 
of the world. India had the greatest number of cases with 
59%, followed by Brazil and Indonesia with 14% and 
8%, respectively [36].
 In the year 2015, the regions reported new cases 
as follows: EUR- 18, SEASR- 56,118, EMR- 446, AFR- 
20,004, AMR- 28,806, and WPR- 3,645 (Table 1). This 
translated into a total of 210,758 new leprosy cases in 
all the 6 regions that year. Pockets of high endemicity 
therefore still remain in some regions of some countries, 
including (countries) reporting less than 1,000 new 
cases, with some of the regions showing very high 
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notification rates for new cases, and likely to witness 
intense transmission [36]. 
 Annual data was availed from 36 countries 
and territories of the Western Pacific Region (WPR) of 
WHO for the year 2009, while 35 countries provided 
data for the year 2010. The goal of eliminating leprosy 
as a public health problem (a prevalence rate below one 
case per 10 000 population), was achieved in 34 (99.9% 
of WPR population) of the 37 WPR. 
 The year 2010 witnessed registration of 8,386 
new cases in WPR, with a prevalence rate of 0.05 per 
10,000 population, and 34 countries had eliminated 
leprosy as a public health problem. Five countries (China, 
Malaysia, Papua New Guinea, the Philippines and Viet 
Nam) contributed to 86% of the total prevalence. The 
Federated States of Micronesia and the Marshall Islands 
never reached leprosy elimination, while Kiribati failed 
to maintain the elimination threshold [29]. 
 The Americas Epidemiologic Region had 33,789 
out of 211,973 new leprosy cases recorded worldwide 
in that year (2015). The disease was reported from 
24 countries of the region with  Argentina, Bolivia, 
Brazil, Colombia, Cuba, Dominican Republic, Ecuador, 
Mexico, Paraguay, and Venezuela reporting more than 
100 new cases. However, 94% of all cases in the Region 
were concentrated in Brazil [38].
 The South-East Asia Epidemiological Region 
accounted for 71% of new cases detected worldwide in 
2012 with 166,445 cases reported. From 16 countries 
reporting more than 1000 new cases, six countries were 
in the South-East Asia Region, namely, Bangladesh, 
India, Indonesia, Myanmar, Nepal and Sir Lanka. 
 The new case detection rate for 2012 is 
9.08/100,000 population. Among new cases detected 
during the reporting year, 16,337 (9.82%) cases were 
children below 15 years of age; and 62,053 (37.28%) 
were women. Registered prevalence: the total number 
of cases registered at the end of 2012 in all member 
states of the region was 125,171 accounted for registered 
prevalence rate of 0.68/10,000 population which was 
below the elimination rate of less than 1 per 10,000 
population [36].
 In the African Region, leprosy prevalence rates 
have dropped from 57,516 cases in 2000 to 33,690 in 
2010, this represents a 42% decrease. A leprosy-induced 
irreversible disability currently affects about one million 
people in the Region. 
 The most vulnerable and high-risk populations 
are living in poor rural areas in the Democratic Republic 
of the Congo, Ethiopia, Madagascar, Mozambique, 
Nigeria and Tanzania [36].
 One of the African Region country experiencing 
a resurgence of leprosy is the East African state of 
Kenya. Since time immemorial, the disease has been 
endemic in parts of the coastal strip and western part 
of the country. This led to the establishment in 1947 
of the ALUPE LEPROSARIUM HOSPITAL at Alupe 
by the government of Kenya. The mandates of the 
Alupe leprosarium includes management of leprosy 
as a referral centre for this disease in East Africa, and 
research on leprosy [39]. 
 The year 2012 saw Kenya notify 127 new and 
8 of relapse cases of leprosy, with infectious multi-
bacillary (MB) forms accounting for 137 of cases. Six 
(6) cases involved children under the age of 14 years 
signifying active and recent transmission. 
 The number of new cases slightly fell in the 
year 2013 to a total of 93 new cases (and 9 relapses), 
with infectious MB forms accounting for 85 of cases. 
However, there was an increase of cases in the year 2014 
to 114 new cases and 12 relapses, with a total 113 of 
them being infectious MB forms [40].
 The country’s 2015 annual report informed 
of  a total of 124 leprosy cases were diagnosed in 22 
counties, notified and enrolled on treatment, with males 
constituting 67% of the cases. Two (2) of the notified 
cases were children between the ages of one and 14 
years (from Kisumu and Taita Taveta Counties), an 
indicator of continuing community transmission, which 
warrants intensive case finding and treatment among 
the community members. The cases were mainly 
distributed along the coastal counties and some parts of 
the western region [41]. 
 Among the 36 leprosy endemic districts in 
Kenya, only 6 of them (Msambweni, Kilifi, Kaloleni, 
Malindi, Kinango and Nyakach) contributed a large 
case load (about 64%), necessitating an investigation 
to determine the underlying drivers in these districts, 
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including the emergence of M. leprae strains resistant 
to anti-leprotics. 
 However, no details were given in this report. 
In the 2016 NTLD Annual Report, leposy was not 
captured.  Also by the time  of writing this article, the 
2013 NTLD annual report could not be located. 
 According the National Strategic Plan for 
Tuberculosis, Leprosy and Lung Health, 2015-2018, a 
total of 139 cases were reported in 2013 [42].
 Kenya had reached the  post-elimination phase 
of leprosy control by 1989, having achieved the WHO 
elimination target of less than 1 case per 10,000 people. 
The number of new reported leprosy cases in the country 
had steadily declined over the past three decades from 
6,558 to 139 cases in 1986 and 2013 respectively [43]. 
 However, the country is currently battling with 
resurgence of the disease, which is characterized with 
high numbers of relapses. For instance in the year 2014, 
there were 12 relapse cases ( Multi-Bacillary, MB ) 
against 114 cases notified that year [44]. 
 Relapses basically mean treatment failure, 
which puts into question the performance of MDT in 
Kenya, calling for an interrogation. In that year (2014) 
some counties reported leprosy cases as follows: Busia 
(10), Bungoma (6), Siaya (11), Kisumu (11), Homa-Bay 
(10), Migori (3), Kwale (49), Mombasa (7), Kilifi (20), 
Garissa (2), West Pokot (1), Bomet (1), Kitui (1) and 
Nairobi (1) [44].  
 These numbers were as a result of passive case 
finding when patients presented themselves to the health 
facilities. This means that there could be many more 
undiagnosed cases in the communities necessitating 
employing the active case finding approach.
 The re-emerged of the disease in Kenya is 
more pronounced at the coastal region of Kenya as 
well as western parts of the country. Active leprosy 
transmission is ongoing and its effects are still being 
felt in specific counties, including Kwale (Msambweni, 
Kinango), Kilifi (Kaloleni, Kilifi, Malindi), Mombasa, 
Kisumu (Nyakach, Muhoroni), Siaya, Homabay, Migori, 
Bungoma, and Busia. Remote areas of Kilifi and Kwale 
counties have the highest number of cases [44]. 
 About 43% of the leprosy cases in Kenya are 
diagnosed with disabilities (grades 1 and 2). This has 
been attributed to patient or health system delay, or 
both. This calls for concerted efforts to train health care 
workers on how to effectively suspect and diagnose 
leprosy cases.The drivers of leprosy resurgence in 
Kenya therefore need to be investigated.
Tabe 2: New Leprosy Cases and Relapses (MB Cases In Parenthesis) Reported By National TB Leprosy and Lung        
 Disease Programme (2007-2016)
Period 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
New 
cases
213 167 157 126 102 127 114 - -
Relapses - - - - - 8 - 12 - -
Total 213(196) 167(153) 157(148) 126(118) 105(94) 135(128)139(?) 126(113) -
Sources: NTLP, Kenya. Annual reports, 2007-2016. https://www.nltp.co.ke/annual-reports/ [40-42; 44-49]
 The data in the above table was obtained from 
annual reports of the Kanya National TB,  Leprosy and 
Lung Disease Programme. The missing information 
(dashes) reveals the weakness in health data collection 
systems in some developing countries, Kenya included. 
 Moreover, it is not clear how it was arrived at 
that the 8 and 12 cases in 2012 and 2014 were truly 
‘relapses’,  since this  would have  required  genotyping 
of M. leprae isolates the first and second episodes.  Or 
else they should have been reported as recurrent. 
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diagnosis of borderline lepromatous leprosy. However, 
the donor of the liver did not show any evidence of 
leprosy, and Trindade and his colleagues couldn’t 
ascertain the source the infection.
 As  M. leprae can persist and possibly proliferate 
in the environment in association with certain plants 
and animals. It is conceivable that, infection may 
result through prolonged or repeated exposure to an 
environmental source containing viable bacilli. This 
is difficult to investigate experimentally because M. 
leprae cannot be cultivated in vitro and evidence can 
only be obtained indirectly through epidemiological 
studies [58, 59]. 
 Moreover, most risk factors for leprosy are 
poverty related. They include illiteracy and low education 
level, malnutrition, frequent contact with natural water 
bodies and an infrequent change of bedding linen (due 
to water shortage and poverty) [53]. 
 An association between a low level of school 
achievements and the incidence of leprosy was also 
demonstrated in a study in Malawi [60]. 
 Education is difficult to interpret at a biological 
level, as those with a low level of education usually come 
from the lowest income stratum of a population and, 
therefore, share many other health hazards, including 
lack of health education and access to health care. Low 
education may therefore be considered as a distant 
determinant of leprosy.
 Malnutrition is a typical characteristic of low-
income households. This factor could be more directly 
related to leprosy. It is conceivable that inadequate 
nutrition weakens the immune competence against 
infection and, thereby, the infection with M. leprae [61]. 
 Alternatively, this factor could represent a 
marker for other health hazards associated with extreme 
poverty such as risky behavior to increased exposure 
[53].
 
 The low frequency of changing bedding linen is 
related to water shortage, poverty, and personal hygiene. 
Observations indicate that, inappropriate hygiene is 
mainly the consequence of water shortage that is much 
more frequent in the poorest areas [53].
 Most workers agree that transmission of leprosy 
is primarily person-to-person in respiratory droplets or 
nasal discharge: the risk of developing leprosy is 5 - 10 
times higher if one member of the family has developed 
the disease previously than otherwise [51, 52] and higher 
if the primary case has lepromatous leprosy and lower if 
tuberculoid leprosy [51,52, 53]. 
 The M. leprae may survive outside a human host 
for a period of hours or even days. Only the lepromatous 
form of the disease is thought to be infectious. While 
human-to-human respiratory transmission is thought 
to be the likely a cause of most infections. Exposure to 
insect vectors, infected soil, and animal reservoirs may 
also be possible modes of transmission 
 Nevertheless, the risk factors for leprosy and 
transmission of the disease are varied. For instance, 
although a family contact increases the risk of leprosy, 
in a typical endemic area the majority of new cases 
cannot be linked to intra-domiciliary contact with a 
leprosy patient [51, 54]. 
 This suggests the existence of unrecognized 
human-to-human contacts or more intriguing other 
modes of transmission [55]. 
 Another study concludes that age of the contact, 
the disease classification of the index patient, physical 
and genetic distance are independently associated with 
the risk of a contact contracting leprosy [56]. 
 Therefore contact surveys in leprosy should not 
only focused on household contacts, but also extended 
to neighbours and consanguineous relatives, especially 
when the patient has paucibacillary (PB) leprosy with 
2-5 lesions (PB2-5) or Multi-bacillary (MB)  leprosy.
 An intriguing observation in Brazil - a case of a 
liver transplant patient who developed  Multi-Bacillary 
leprosy. They quipped this to be the first case, to their 
knowledge, of such a patient who developing the disease 
[57]. 
 The patient presented with papules and 
infiltrated plaques with loss of sensation suggestive of 
leprosy 3.5 years after living-related liver transplantation 
for autoimmune hepatitis. A skin biopsy showing non-
caseating macrophagic granulomas, neuritis, and intact 
acid-fast bacilli on Fite-Faraco stain, confirmed the 
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  If water is limited, the person responsible for 
household chores (usually the mother) may refrain from 
frequently changing bed-linen; or irregular change of 
bed-linen may be a behavioural characteristic linked to 
inappropriate hygiene perception. M. leprae can survive 
out of the human body for several months even under 
unfavorable conditions [59]. 
 It is possible that this behaviour could maintain 
the M. leprae in the bed and facilitate longer contact and 
transmission to the user [53]. 
 Water shortage is frequent in semi-arid regions. 
In some countries, this has driven rural populations to 
migrate to suburbs (slumy areas) of more developed cities 
and this has been shown previously to be associated 
with leprosy [62].
 Another risk factor with strong association with 
leprosy is frequent contact with water bodies such as 
springs, streams, rivers, ponds, or lakes for recreational 
activities. In the semi-arid climates, seasonal rivers have 
running water only during the rainy season and when 
precipitation stops, pools of stagnant water remain, or 
are dug by the population, and become a habitat for a 
variety of plants and small animals. 
  Similarly, ponds and lakes transform 
into swamps covered thickly with vegetation in which 
small pools of water remain. All these sources of water 
are used by people for recreation and, if households 
have no access to piped water or a well, they use them 
for domestic purposes as well [53] 
 It is known that viable M. leprae may persist 
and proliferate in water plants such as Sphagnum 
species even in cold-climate countries [58] and water 
has been repeatedly suggested as a reservoir for M. 
leprae [63]. Interestingly, water has been considered 
a putative source of infection with M. leprae already 
in the early days of leprology. Hansen and Looft [64] 
observed that in Norway (where the West Coast was 
a hyperendemic area during the 19th century) leprosy 
lesions were commonly located at the feet and the lower 
legs. 
 In those times many people walked barefooted 
(at least during summer) and had to cross rivers and 
swamps to reach their fields or neighbouring villages. 
According to Hansen and Looft, sores acquired when 
walking barefooted facilitated the infection with M. 
leprae in a similar way to that proposed for M. ulcerans 
today. 
 Before this study, evidence to this hypothesis 
. Using M. leprae-specific DNA probes, they showed 
that in Indonesia, the prevalence of leprosy among 
individuals who used water sources containing M. 
leprae for bathing and washing clothes or dishes was 
significantly higher than that among individuals who 
used water free of M. leprae [65]. 
 
 A study indicating that individuals with a 
successful BCG vaccination (as indicated by the typical 
scar) were protected against leprosy (OR = 0.48; 95% 
CI 0.33–0.70). This observation confirmed previous 
findings which suggested that, BCG vaccination partly 
protects against the development of leprosy [53, 66].
 However, it is a characteristic of leprosy that 
it is virtually impossible to precisely assess time and 
duration of exposure and the onset of an infection. It is, 
therefore, an intrinsic weakness of any epidemiological 
approach that owing to the long and variable incubation 
period risk factors have to be looked for [53].
 In that case–control, the study conclude 
that certain socio-economic, environmental, and 
behavioural risk factors exist, which favour the 
occurrence of leprosy in an endemic area and could be 
targeted in control measures encompassing more than 
implementation of Multi-Drug therapy. The observation 
that frequent contact with natural water bodies is a risk 
factor for leprosy and Socio-Economic variables make 
stronger the notion that water or wet soil may act as a 
reservoir for M. leprae.
The Biology of Mycobacterium 
leprae and leprosy
 Like others members of the genus 
Mycobacterium, M. leprae is an acid-fast Gram-positive 
bacillus with a mycolic acid- rich cell wall and a single 
membrane. The M. leprae still remains uncultivatible 
in vitro despite nearly 150 years of effort to develop a 
suitable laboratory culture method. 
 The orgnism, however, grows in armadillos 
(Dasypus novemcinctus) after subcutaneous and and 
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intravenous inoculation; the bacilli may be recovered in 
large quantities from various organs such as the skin, 
lymph nodes, liver, kidneys and spleen. The organism 
grows when inoculated into the footpads of athymic 
nude mice,  which lack normal thymus gland, and have 
defective immune system because of a genetic mutation 
[67, 68]. 
 Modern M. leprae strains are currently divided 
into 5 phylogenetic groups, types 0 to 4, each with 
strong geographical links. Until recently, European 
strains, both ancient and modern, were thought to be 
exclusively type 3 strains. 
 Eventually, evidence for type 2 strains, a group 
normally associated with Central Asia and the Middle 
East, has recently been found in archaeological samples 
in Scandinavia and from two skeletons from the 
medieval leprosy hospital (or leprosarium) of St Mary 
Magdalen, near Winchester, England [3].
 The genome of M. leprae consists of 
3,268,203 base pairs (bp), compared with the genome 
Mycobacterium tuberculosis that has 4,411,529 bp. The 
number of expressed genes of M. leprae is approximately 
60% fewer than that of M. tuberculosis. 
 Since both M. leprae and M. Tuberculosis 
probably evolved from a common Mycobacterial 
ancestor, M. leprae appears to have lost approximately 
2000 genes since their divergence, leaving it dependent 
on specialized ecologic niches for survival. The genes 
lacking in M. leprae include those of the mbt complex, 
whose products are essential in the acquisition of iron. 
 The M. leprae also lacks many of the genes 
essential for lipid biosynthesis and modifications that 
are characteristic of M. tuberculosis. The sequencing of 
M. leprae genome has also allowed a directed approach 
to identification of 16 “strains” of M. leprae from 
geographically diverse sources [67, 69]. 
 Generally, the genome of M. leprae predicts 
severe metabolic restrictions due to a multitude of gene 
disruptions and deletions. Due to unavailability of an 
in vitro culture method for M. leprae in vitro, animal 
models such as armadillos and nude mice continue to 
provide a basis for testing new drugs and vaccines and 
offer insight into basic mechanisms of pathogenesis 
[70].
 The M. leprae has the longest generation 
(doubling) time of all known bacteria and has thwarted 
every effort into in vitro culture. Comparing the 3.27- 
megabase (Mb) genome sequence of an armadillo-
derived Indian isolate of the M. leprae with that of M. 
tuberculosis (4.41 Mb) provides clear explanations for 
the latter’s long generation time and non-culturability in 
vitro. 
 It also reveals an extreme case of reductive 
evolution. Less than half of the genome M. leprae 
contains functional genes, but pseudogenes are 
bound, compared with their intact counterparts in M. 
Tuberculosis. 
 The genome scale down and the current mosaic 
arrangement in M. leprae might have resulted from 
extensive recombinations between dispersed repetitive 
sequences. Gene deletion and decay eliminated many 
essential metabolic activities such as the production 
of siderophore, part of the oxidative and most of the 
Microaerophilic and anaerobic respiratory chains, 
and numerous catabolic systems and their regulatory 
circuits [69].
 The complex cell structure and deficient 
metabolic pathways of M. leprae are worthy deeply 
examining for researchers to mount a sucessifull against 
this organism. As already noted, M. leprae is an acid 
fast Gram-positive bacterium, with a slow generation 
(doubling) time of 14 days. 
 The slow doubling time is due to the restricted 
intake of nutrients through the pores in the large waxy 
walls. Like other mycobacteria, M. leprae have a unique 
lipid that makes up their membranes that gives them 
their unique characteristic. The mycolic acids are very 
large lipids with chains ranging from 60 to 80 carbons 
long [69]. 
 Covalent bonds link these lipids to one another 
forming a very thick surrounding that is solid at room 
temperature. This large hydrophobic shell prevents 
polar molecules, such as germicides commonly used 
in hospitals, from entering the cell. The slow doubling 
time is common in other mycobacteria, it also makes it 
particularly hard to fight M. leprae through development 
of appropriate interventions [69, 71].
 Many of the pseudogenes primarily occur in the 
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metabolic pathways. Entire metabolic pathways have 
been lost to this genomic down sizing. M. leprae can 
no longer produce siderophores, a key part of oxidative, 
microaerophilic and anaerobic chains [72]. 
 Many regulatory elements of metabolism have 
also been lost and also many catabolic pathways too. 
M. leprae has five different membrane proteins that are 
used to import lipids into the cell. The primary carbon 
source for M. lepraeis lipids. The most conserved set 
of catabolic enzymes are those involved with beta 
oxidations. The primary source of ATP is from the 
Krebs cycle. The electron transport chain is severely 
restricted, and isn’t very efficient [71]. 
 The M. leprae is dependent on the host cell to 
provide many of the nutrients and metabolites. This 
coupled metabolism shows how M. leprae has evolved 
as into a parasitic role. In the laboratory it was found 
that ideal metabolism (based on ATP synthesis) occurs 
at 33 oC and at a pH between 5.1 and 5.6 [73].
 Another interesting aspect of leprosy is the 
ecology bof the aetiolgic agent. Like other members of 
the genus Mycobacterium, M. leprae is suspected to be 
found in the soil, but due to the fact that it can not be 
plated it is hard to conclude that this is the case [74]. 
 The DNA of  M. leprae has been found in several 
soil samples within areas known to house outbreaks of 
leprosy before. Leprosy is very specified when it comes 
to infecting hosts. Its ideal conditions are around 33OC, 
which is lower than most mammals. Mammals with 
lower temperatures are better hosts for leprosy. 
 That is why only a few species are known to 
be carriers of M. leprae. This is also why in humans, 
leprosy tends to be found primarily at the peripheral 
nerves. Hands and feet tend to be cooler than the 
core body temperature, providing a more habitable 
environment for M. leprae [72, 73, 75]. 
 The M. leprae infects the human skin as it 
thrives best at temperatures somewhat lower than inside 
the body. The organism also has an affinity for nerve 
cells, explaining why leprosy is characterized by loss 
of feeling on the skin surface. The M. leprae is the only 
member Mycobacterium genus known to infect or has 
tropism for nervous tissue [1]. 
 However, the actual mechanism of M. leprae 
infection still remains a mystery surrounding this 
obligate intracellular pathogen. Recently a gene has 
been discovered that plays a great role in cellular 
infection. The mce1A gene, that translated into a protein 
that causes an uptake into mammalian epithelial cells, 
has shed some light on the mysterious infection pathway 
of the organism [76]. Another area of focus has been M. 
leprae interaction with the cytokine signaling pathway. 
Cytokines are extracellular proteins that are essential 
for proliferation and maturation of human cells. 
 The M. leprae interferes with these signals, 
preventing maturation and apoptosis. This prevents 
the host from voluntary causing cells to die to remove 
infected cells [77]. Another similar pathway was 
recently found involving tyrosine kinases. This is 
another pathway that promotes cellular proliferation 
[78].
Leprosy and M. Leprae Drug 
Resistance
 The current recommended control measures 
for treating leprosy with Multi-Drug Therapy (MDT) 
are designed to prevent the spread of drug-resistant M. 
leprae strains. Despite that, drug resistance has been 
reported since 1964 for Dapsone, 1976 for Rifampin 
[80], and since 1996 for Ofloxacin. Transmission of 
M. lepare strains resistant to Dapsone is also on the 
increase [76, 79,80, 81]. 
 Drug resistance detected by molecular tests is 
also being reported from several countries through the 
current WHO drug surveillance campaign. 
 However, this is largely a voluntary limited 
exercise for relapse cases. Molecular surveillance of 
resistance to anti-leprotic therapies and M. leprae strain 
typing by mapping variable-number tandem repeats 
(VNTRs) and single-nucleotide polymorphisms (SNPs), 
have applications in tracing transmission of the disease 
and in monitoring the efficacy of control programmes 
[82, 83, 84, 85]. 
 With the emergence of Dapsone resistance, 
Multi-drug Therapy (MDT), which consists of 
Dapsone and Rifampin for Paucibacillary leprosy and 
the additional drug clofazimine for Multi-Bacillary 
(MB) leprosy, was introduced by the World Health 
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Organization in the 1980s [86]. 
 As reports of Rifampin and dapsone resistance 
in several countries began appearing, the WHO initiated 
a surveillance programme, particularly for relapse 
patients [82,87,88]. 
 Until recently, clinical drug resistance was 
detected by Mouse Footpad (MFP) Assays, which 
require specialized facilities and 6 to 12 months to 
achieve results [88]. 
 On the other hand, PCR amplification followed 
by sequencing of the Drug Resistance-Determining 
Regions (DRDRs) in folP1 and rpoB genes can detect 
resistance to Dapsone (diamino-diphenyl Sulphone, 
DDS) and Rifampin. Fluoroquinolones, which are 
alternative drugs for leprosy, target the gyrase, encoded 
by gyrA and gyrB [89].
Prevention and Treatment Of 
Leprosy 
 In the 1990s, the WHO established a goal of 
eliminating leprosy as a public health problem by the 
year 2000; "elimination" was defined as a reduction in 
prevalence to less than one case per 10,000 population 
in all endemic countries [30]. 
 
 The strong commitment of national 
governments, together with technical guidance from 
WHO, sustained support of donors, availability of 
MDT, long-term collaboration with non-governmental 
organizations and the participation of networks of 
persons affected by leprosy, has resulted in a reduction 
in prevalence rates from more 5 million cases in the 
mid-1980s to less than200,000 cases at the end of 2016. 
 The reduction in prevalence to less than one 
case per 10,000 population at global level by 2000 
and subsequently at national level in most endemic 
countries by 2005 marked a significant milestone in the 
elimination of leprosy as a public health problem [37]. 
Nonetheless, new cases continue to occur.
 To control and greatly reduce the burden of 
leprosy, the WHO [90] launched a 5-year global leprosy 
strategy:
1. The strategy is built around 3 pillars: 
 a. To strengthen government ownership,  
  coordination and partnership.
  b. To stop leprosy and its complications.  
 
 c. To stop discrimination and promote  
  inclusion. 
The strategy set 3 main targets at global level to be 
achieved by 2020. 
These were:
1. A reduction to zero cases of new Grade 2 disability 
(G2D) child cases.
2. A reduction in the rate of new G2D cases to less 
than 1 case per one million population (from G2D 
rate of 2.5 per million population at the end of 
2015
3. Zero countries with laws or legislation that 
allow discrimination against leprosy (6 countries 
reported active legislation allowing discrimination 
on the basis of leprosy in 2015). 
    To define the baseline for the strategy, further 
information is required from all countries on new G2D 
child cases and number of active laws or legislation that 
discriminate on the basis of leprosy [37]. 
 However, the best way to prevent transmission 
of leprosy is early diagnosis and prompt full course of 
treatment of leprosy cases with Multi-Drug Therapy 
(MDT).
 MTCs are critical for preventing lifelong 
neuropathy and disability in leprosy patients. For 
household contacts, immediate and annual examinations 
are recommended for at least five years after last contact 
with a person who is infectious [29, 90, 91]. 
 Treatment is specific to the type of leprosy and 
severity of the condition.
Tuberculoid leprosy; 
 is a mild, less severe and less contagious form  
 of leprosy.
Lepromatous leprosy;
  is more severe and is characterized by   
 widespread skin bumps, rashes, numbness and  
 weak muscles [90].
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 In Kenya for instance, the regimen that 
is being used to treat leprosy is Multiple Drug 
Therapy (MDT), as advocated by the WHO. 
Multiple drug therapy was introduced in 1984 and 
replaced Dapsone monotherapy. The MDT differs 
from mono-therapy (initially used in leprosy 
treatment) in being a combination of several 
powerful anti-leprotic drugs. 
Source: DLTLD, Ministry of Public Health and Sanitation, Government of Kenya, 2009 
Table 2. The MDT Treament For Pauci-Bacillary Leprosy (PB) Patients (Duration Six Months)
Age 0 - 5 years 6 - 14 years >14 years
Dapsone daily 25 mg 50 mg 100 mg
Rifampicin 
Four -weekly supervised 150 mg 300 mg 600 mg
Table 3. The Mdttreatment For Multi-Bacillary Leprosy (MB) Patients (Duration One Year)
Age 0 - 5 years 6 - 14 years > 14 years
Dapsone daily 25 mg 50 mg 100 mg
Clofazimine (Lamprene)
 Four-weekly supervised 50 mg alternate days 50 mg daily 50 mg daily
Clofazimine (Lamprene) 
Unsupervised 50 mg alternate days 50 mg daily 50 mg daily
Rifampicin four-weekly 
Supervised 150 mg 300 mg 600 mg
Source: DLTLD, Ministry of Public Health and Sanitation, Government of Kenya, 2009.
 This combination prevents the development of 
drug resistant bacilli, and has shortened the duration 
of treatment to six months in pauci-bacillary leprosy 
and to one year in multi-bacillary leprosy (Tables 2 
and 3) [46]. 
 There have been concerted efforts to enhance 
healthcare workers (HCW) skills in diagnosing leprosy. 
 A training curriculum (for Kenya) is in place 
and HCW trainings have been conducted since 2016 
especially in high endemic areas. Resource mobilization 
for post elimination strategies for Leprosy is also on 
going [46].
Leprosy prevention and 
control challenges and their 
mitigation 
 Elsewhere this article has already sated that 
leprosy is a curable disease with well-defned aetiology, 
but lacks suitable diagnostic tools and markers, 
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preventive and therapeutic strategies [92]. Worsening 
this already bad situation is the unpredictable 
development of a vaccine agaist the disease in the near 
future.
 The use of prevalence rate for the elimination 
of leprosy has sparked debate for many years, because 
of its sensitivity to treatment duration and the fact that 
annual cases detected have not declined globally since 
1985 [93]. 
 The prevalence of leprosy declined very fast 
with the introduction of MDT because of the reduction 
in the duration of treatment of the disease  from over 
five years to 12 months in the case of MB. 
 As at the end of 2006 only six (6) countries in the 
world were reported not have  achieved the elimination 
goal. They were Brazil, Democratic Republic of  Congo, 
Madagascar, Mozambique, Nepal and United Republic 
of Tanzania [94].
 Lack of common understanding of the definition 
of “elimination” between technical groups and policy 
makers is also a huge challenge. 
 The WHO defined Leprosy elimination in 
terms of Leprosy prevalence reduction to a level that 
it ceases to be a ‘Public Health Problem’. It is different 
from the concept of disease elimination 
“Defined as a reduction to zero level
 in the incidence of infection 
caused by a specific agent 
in a defined geographical area 
as a result of deliberate efforts,"
but requires measure to prevent reestablishment of 
transmission [95]. 
 Alternatefly, eradication suggests zero 
incidence and zero transmission of the disease agents. 
Leprosy eradication was based on the assumption that, 
after achieving elimination target, leprosy would die out 
periodically provided all leprosy services continued to 
be available [96]. 
 This assumption may have, contributed to the 
low government commitment experienced in many 
countries after achieving the elimination target.   
Moreover, governments of countries including those 
experiencing leprosy resurgence show low commitment 
towards funding the health sector. 
 Their national health financing policies are 
skewed in favour of sectors such security and governance 
as priority areas, with budgetary allocations 3-5 fold that 
of health.  In some other countries, budgetary allocation 
to health is influenced by political dynamics [97]. 
 It is prudent to continue supporting current 
strategies, put in place stringent evaluation of leprosy 
services and their results to ensure, integration of 
leprosy services has  the desired effect on the disease. 
 There is need for continued pursuance or the 
search for new tools whose appropriate application will 
inform better control practices that will lead to improved 
services and eventually the eradication of leprosy [98].
 Leprosy presents a variable incubation period 
ranging from 6 months to more than 20 years (average, 
2–4 years), due to its very slow growth [99]. 
 The M. leprae is also currently not culturable 
in the laboratory, hindering noble leprosy research such 
as novel vaccine and drug development. Leprosy has no 
primary prevention, which means there is no specific 
vaccine against M. leprae [100]. 
 The BCG vaccine specifically developed for 
tuberculosis offers  about 50% protection against leprosy. 
Also due to lack of a suitable culture technique and long 
generation time (14 days) of M. leprae, diagnostics and 
prognostic tests are not feasible nor well established in 
clinical routine [2].
 Molecular and immunological tests have been 
developed for leprosy diagnostics and prognostics. 
Among these tools, the Polymerase Chain Reaction 
(PCR) and its variations, ELISA (Enzyme-Linked 
Immunosorbent Assay) and other serological tests are 
the main technologies employed with different markers 
and strategies. 
 However, variations in PCR positivity, mainly 
due to the different primers, amplified fragment sizes, 
and amplifcation techniques have been observed [92]. 
 Moreover, molecular tests are relatively 
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expensive and require more skilled labour. Most of them 
also have low utility for point - of – care diagnosis. 
 
 The identification of specific informative 
diagnostic antigens is one of the most difficult aspects 
in developing new diagnostic tools. This is particularly 
true with leprosy, since there is a paucity of information 
involving the roles of many of the expressed proteins or 
the metabolic state of the organism throughout infection 
and disease progression [101]. 
 Many studies have exploited genomic and 
proteomic sequences for the identification of M. leprae-
specific proteins or peptides that may be suitable for 
serodiagnosis of different disease states of leprosy. 
Many of these studies have described novel antigens that 
show marked humoral and cellular immunogenicity. 
 However, none of have reached useful accuracy 
in terms of sensitivity and specificity – they are 
essentially non-specific and of low sensitivity [92].
 Tests that measure cellular immunity to 
mycobacteria have historically relied on the use of 
mycobacterial extracts, or purified complex mixtures 
of mycobacterial components. In leprosy, purified 
M. leprae was initially used in the lepromin skin test 
[], followed later by the use of soluble extracts of the 
bacillus, designated leprosin [ 102, 103]. 
 In tuberculosis, purified protein derivative of 
boiled M. tuberculosis has been used since the beginning 
of the last century in the classical Tuberculin Skin Test 
(TST). 
 The diagnostic value of almost all of these 
tests is compromised by the presence of conserved, 
immunologically cross-reactive components that are 
shared with other mycobacteria, which results in low 
test specificity. For leprosy, such cross reactivity is 
particularly problematic in countries with high incidence 
rates of tuberculosis. Routine BCG vaccination 
practice, and high levels of exposure to non-pathogenic 
environmental mycobacteria [104].
 Specific tests are needed to distinguish previous 
infection with M. tuberculosis or M. leprae from each 
other as well as from exposure to other mycobacteria, 
including BCG [105]. 
 However, it has been demonstrated that the 
specific cellular response raised by the Mitsuda test 
(reaction > 7 mm) may be an indicator of acquired 
protective immunity rather than an expression of 
hypersensitivity in household contacts [106]. 
 The search for M. leprae antigens for improved 
leprosy diagnosis still remains a challenge. There are 
many potential targets, albeit most of them having only 
preliminary results in Cell Culture Stimulation Assays 
and lack either specificity or sensitivity for the detection 
of asymptomatic infections and disease progression 
[101].
 Measurement of humoral immunity has mainly 
relied on detection of circulating antibodies against the 
M. leprae phenolic glycolipid-1 (PGL-1) antigen [107]. 
 The M. leprae infection can be detected by the 
presence of elevated titres of IgM antibodies against 
PGL-1, and may be a reflection of total bacterial load 
in the body than the bacilloscopic index of a local skin 
smear [108]. 
 However, the IgM antibodies are generally 
low or absent in Paucibacillary patients. A sensitive 
and specific method to identify subclinical M. leprae 
infection is yet to be developed [101].
 There is no specific vaccine against M. leprae. 
The BCG vaccine is estimated to provide about 50% 
protection against leprosy [109].  
 The M. leprae is still a great challenge for 
research development due to the possibility of eliciting 
a complex immunological response that could lead to 
neural damage in asymptomatic individuals. It is well 
known that the protective immunity is the cellular 
response, which is responsible for the pathogenesis of 
the nerve injury, and the humoral response does not 
protect against the bacilli dissemination [92].
 Lack of sufficient knowledge and skills 
among community (peripheral) healthcare workers is 
a significant challenge. Some community healthcare 
workers in some low income Countries do not have 
professional training.
 Hence, have unsatisfactory knowledge and 
skills for leprosy prevention, control and management. 
This may lead to missed early case detection of new 
leprosy cases, and appropriate dealing with leprosy 
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complications / disability and rehabilitation [110]. 
 From the foregoing, the mitigation of the 
challenges encountered in the prevention and control of 
leprosy revolves around:
 a. The resolution of issues pertaining the  
  irrational and retrogressive believes. 
 
 b. Sociology of the disease.
 
 c. Development of robust novel   
  vaccine(s) and diagnostics. 
 
 d. Development of novel ant-leproics and  
  advocacy.
 Advocacy for political goodwill will be of great 
value. Advocacy to governments / partners / and all 
other stakeholders for increased resource allocation, 
support for leprosy prevention and control activities is 
of cardinal significance. 
 Advocacy to influence policy and decision 
makers to formulate favourable laws and regulations 
for leprosy including out-lawing discrimination against 
the disease and formation of collaborative partnerships 
among various actors will yield better results [97].
 Health education and counselling of persons 
with leprosy, their family members close contacts and 
the community in general, need spiritual counselling to 
dissuade people from believes that, leprosy is a curse 
from God for their sins or the disease is heritable. 
This will reduce the stigma, improve health seeking 
behaviour of leprosy patients, prevention and control. 
 Appropriate counselling will provide 
psychological support, appropriate education and 
coping skills to persons affected by adverse events of 
leprosy. Counselling of leprosy patients is essential to 
enable them to cope with perceived stigma as well as 
managing severe enacted stigma at home, place of work 
or elsewhere [111]. 
 Empowerment of healthcare workers (HCWs) 
with more skills in the prevention, control and 
management of leprosy, economic empowerment, 
rehabilitation and social support for the already 
deformed persons will be worthy investing in [112].
Challenges Faced 
By Persons With Leprosy 
 To date, leprosy is among the most debilitating 
diseases known to mankind. Victims and their families 
are weighed down with a huge burden due to the 
physical, mental and socioeconomic consequences [82].
 Persons suffering from leprosy face numerous 
indignities every day in many countries. Once diagnosed 
with leprosy, patients face the long and uphill task of 
recovering and reintegrating into their community. 
Employers regularly turn away people who have the 
disease even if they have been treated and cured. Often 
people diagnosed with leprosy hide their condition from 
their families and loved ones, out of fear that they will 
be ostracized from the community. 
 In some countries obtaining legal documents 
such as a driver’s license and business license, among 
others is very difficult. Often the disease free children 
of parents with leprosy are shunned by the communities 
they live in [113].
 The real challenge confronting persons 
with leprosy is persistent stigma, prejudice and 
misunderstanding of leprosy, which continue to be 
stubborn to overcome. 
 Evidence suggests that a staggering number of 
individuals are at risk of being left behind, burdened 
by low self-esteem, subject to low expectations and 
diminished in their ability to pursue their dreams. 
 Leprosy, related disability disproportionately 
affect women, children and older people.  Persons 
suffering from leprosy, related disability and those 
with disability face widespread barriers to accessing 
services, and experience significantly poorer health 
outcomes [113].
 The most obvious consequence of leprosy is 
as a result of physical disabilities that make it difficult 
for the victims to perform regular duties. All leprosy 
patients are at risk of developing disability at any time. 
This may diminish the status of the affected person and 
lead to psychosocial torture among other sufferings for 
the rest of their life. 
 Disability and deformity primarily result 
directly or indirectly from function loss of peripheral 
nerves, supplying eyes, hands and/or feet [114]. 
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 Leprosy does not only affect day-to-day 
functioning in the family, but considerable restrictions 
are imposed on patients due to the fear of social stigma. 
 The disease may exert great pressure on the 
relationships of leprosy sufferers such as marriage. 
Divorce rate among the leprosy sufferers is relatively 
high. Segregation and institutionalization are in some 
cases a direct outflow of the rejection that people affected 
by leprosy experience from the broad community [115]. 
 Stigma resulting in discrimination and social 
exclusion can have a major impact on one's quality of 
life. Self - stigma causes people to hide their condition 
or to withdraw from normal social participation [112].
 Scott argues that leprosy strongly influences the 
behaviours of people affected. The disease can affect a 
patients’ manners in their entire life. The high rate of 
suicidal attempts highlights the patients’ concept of the 
psychological disorder as a result of leprosy [115]. 
 Regardless of religious and cultural orientations 
among different societies, leprosy has commonly been 
associated with sin, impurity and rejection incurred 
from God as a punishment. This leads to rejection and 
isolation of leprosy patients by their communities [116].
 
 Economic deprivation is another adverse 
consequence of leprosy. The well being and the self-
esteem of a person affected by leprosy are associated 
with their income generation and the capability to secure 
employment. In a culture where a person is valued 
by the ability to support dependents, unemployment 
because of leprosy can have a longterm negative impact 
economically [117]. 
 When the income generation of the leprosy 
sufferer is affected, their families encounter economic 
problems often depriving them of their daily necessities. 
As people affected by leprosy are discriminated from 
participating in the economic activities, they become 
isolated and lose self-confidence. 
 Frustrations with employment, finally force 
patients into alcoholism, begging and adoption of a 
hostile attitude towards society. Unfortunately, a leper 
may be forced to leave his or her home [115].
Conclusions
1. Leprosy is an ancient disease that remains a crucial 
health challenge to date, with some communities 
still believing it to be a curse from God, hence 
hindering seeking of healthcare, 
2. The drivers of the continued endemicity 
and increasing incidence of leprosy in some 
epidemiologic regions including parts of Kenya 
include stigma, lack or little knowledge among 
the world citizenry about the disease, relented 
of control efforts by relevant health authorities, 
emergence of drug resistant strains of M. leprae, 
increased population of immunocomprised 
persons,
 3 In vitro culture of M. leprae is made difficult due to 
massive loss of genes including those essential for 
metabolic pathways, which is a huge impediment 
to leprosy research.
 
4. Leprosy is one of the neglected tropical diseases 
given low priority by national governments 
leading to meager investment in the disease in 
terms of research capacity building.
5. Lack of (formal) collaboration and partnership 
between governments and local communities' 
efforts to control the disease is responsible for the 
continued endemicity and increasing incidence of 
leprosy in some epidemiologic regions.  
Recommendations
 In the light of continued endemicity and 
increasing incidence of leprosy in some epidemiologic 
regions, including parts of Kenya in Africa, there is 
need to consider the following:
1. Identify the socio - cultural, behavioural, socio-
economic, demographic and environmental 
factors associated with the endemicity and re-
emerging / increasing incidence of leprosy,
2. Determine the association between the level of 
body immunity and development of leprosy.
3. Determine the characteristics and distribution of 
M. leprae strains and their Anti-Leprotic Drug 
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Resistance / susceptibility patterns as this is of 
cardinal significance in effective management and 
control the disease, 
4. Significantly, invest in training and enhancing 
skills of health personnel at all levels. Intensify 
basic and applied leprosy research aimed at 
developing rapid diagnostic methods, novel 
vaccines, and more efficacious anti-leprotic drugs, 
5. Build partnerships, engage governments and 
local communities aimed at empowering, 
promoting community involvement through 
educational interventions and campaigns. Which 
will be socially, culturally, spiritually acceptable 
and scientifically sound. This will enable the 
communities to participate meaningfully in 
resolving the hidden challenges of undiagnosed 
cases, halt ongoing transmission.
 
 Implementing the above recommendations will 
achieve better epidemiological control and effective 
monitoring of the disease, hence reduced morbidity 
and mortality, reduced human suffering, and improved 
quality of life. This will meaningfully contribute 
towards meeting various United Nations’ Sustainable 
Development Goals, particularly Goal 3 that seeks to 
“Ensure healthy lives and promote 
well-being for all at all ages”.
facilitate and encourage students’
participation. 
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